Skip to main navigation Skip to search Skip to main content

Co-delivery of 5-fluorouracil and oxali-palladium via β-lactoglobulin nano-capsules coated with Low Methoxyl Pectin for colon cancer therapy

  • Amineh Leilabadi-Asl
  • , Behafarid Ghalandari
  • , Adeleh Divsalar*
  • , Ashkan Zare Karizak
  • , Thomas Haertlé
  • , Xianting Ding
  • , Ali Akbar Saboury
  • , Farnaz Ghorbani
  • *Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

7 Citations (Scopus)

Abstract

Chemotherapy is associated with serious side effects in terms of its high toxicity. Optimizing nanoscale drug delivery systems offers a way to overcome these side effects in cancer treatment. This research studies the synthesis and optimization of β-lactoglobulin (β-LG) nanocapsules coated with Low Methoxyl Pectin (LMP) for the simultaneous delivery of two major drugs, 5-fluorouracil (5-FU) and Oxali-palladium, used for colon cancer chemotherapy. The current research investigates the co-delivery system's physical characteristics, drug loading, and in vitro drug release, as well as its toxicity against the colon cancer cell line. Our findings show that the present co-delivery system uniformly forms, especially at pH 4.5, and has a size <120 nm, this being well optimized for colon cancer cell pores. Moreover, this co-delivery system demonstrates drug encapsulation efficiency of more than 60% for both drugs. Furthermore, it has shown stability and resistance to low-pH acidic conditions. In contrast, it shows the sensitivity to alkaline conditions, which determines that the co-delivery system is optimized for the colon cancer environment. The in vitro drug release results confirm these findings as the highest release rate is associated with the simulated colon cancer conditions. Hence, the present co-delivery system shows higher cytotoxicity toward colon cancer cell lines when compared to free drugs. An in-depth optimization of the co-delivery system of 5-FU and Oxali-palladium using β-LG and LMP is provided, which promotes the development of a protein-based co-delivery system at the nanoscale. Finally, it can be concluded that the presented co-delivery system is very promising to be used in oral drug delivery for colon cancer treatment.

Original languageEnglish
Article number105010
Number of pages8
JournalJournal of Drug Delivery Science and Technology
Volume89
Early online date28 Sept 2023
DOIs
Publication statusPublished - 1 Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier B.V.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 5-Fluorouracil
  • Colorectal cancer
  • Nano-capsule
  • Oxali-palladium
  • β-Lactoglobulin

Fingerprint

Dive into the research topics of 'Co-delivery of 5-fluorouracil and oxali-palladium via β-lactoglobulin nano-capsules coated with Low Methoxyl Pectin for colon cancer therapy'. Together they form a unique fingerprint.

Cite this